期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

SRE元件报告质粒构建、转染和活性测定 被引量：2

Construction,transfection and activity evaluation of luciferase reporter plasmid containing SRE element
下载PDF
导出
摘要 固醇调节元件结合蛋白(SREBP)是机体调控脂质合成的重要转录因子,其作用靶标是所调控基因启动子区域的SRE元件,构建该元件报告质粒对于评价SREBP相关活性物质的作用机制具有重要意义。文章扩增或人工合成了人LDLr基因启动子区域SRE元件1次重复片段或3次重复片段,将其插入荧光素酶报告基因载体pGL3-basic中,构建了2种含有人SRE元件的荧光素酶报告质粒;将该报告质粒转染到人肝癌细胞HepG2中,胰岛素处理可以显著活化荧光素报告质粒,而25-羟基胆固醇和胆固醇结合处理可以强烈抑制。结果表明,所构建的质粒能成功地反映SREBP活性的改变,为体外快速检测SREBP活性相关调控物质提供了一个有效的平台。 SREBP is an important transcription factor, which can regulate lipid synthesis. Its action target is SRE element in the promoter region of regulated gene. Therefore, the construction of lucifer- ase reporter plasmids containing SRE element is significant for the mechanism evaluation of SREBP associated bioactive compounds. In this paper, two kinds of luciferase reporter plasmids containing human SRE element were constructed by inserting cloned one repeated or synthetized three repeated SRE element fragments from human LDLr promoter into a luciferase reporter vector pGL3-basic. Next, these report plasmids were transfected into HepG2 cell line and tile activities of luciferase were characterized. The treatment of insulin could activate the luciferase reporter plasmids and the combi- nation of 25-hydroxycholesterol and cholesterol treatment could inhibit their activity. The results showed that the lueiferase reporter successfully reflected the alteration of SREBP activity, and it would be an effective and rapid platform for screening SREBP activity related substances.
作者 张弦 王友平 刘璐 刘健
机构地区 合肥工业大学生物与食品工程学院
出处 《合肥工业大学学报（自然科学版）》 CAS CSCD 北大核心 2014年第1期110-113,共4页 Journal of Hefei University of Technology：Natural Science
基金 安徽省自然科学基金资助项目(11040606M92)
关键词 SRE元件 荧光素酶报告质粒 活性测定 SRE element luciferase reporter plasmid activity evaluation
分类号 Q786 [生物学—分子生物学]
  • 相关文献

参考文献13

  • 1Goldstein J L,DeBose-Boyd R A,Brown M S. Protein sen-sors for membrane sterols[J].{H}CELL,2006,(1):35-46.
  • 2Horton J D,Goldstein J L,Brown M S. SREBPs:activators of the complete program of cholesterol and fatty acid syn-thesis in the liver[J].{H}Journal of Clinical Investigation,2002,(9):1125-1131.
  • 3Horton J D,Shah N A,Warrington J A. Combined a-nalysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes[J].{H}Proceedings of the National Academy of Sciences(USA),2003,(21):12027-12032.
  • 4Amemiya-Kudo M,Shimano H,Hasty A H. Tran-scriptional activities of nuclear SREBP-1a,-1c,and-2 to dif-ferent target promoters of lipogenic and cholesterogenic genes[J].{H}Journal of Lipid Research,2002,(8):1220-1235.
  • 5Briggs M R,Yokoyama C,Wang X. Nuclear protein that binds sterol regulatory element of low density lipopro-tein receptor promoter,I:Identification of the protein and delineation of its target nucleotide sequence[J].{H}Journal of Biological Chemistry,1993,(19):14490-14496.
  • 6Liu J W,Ahlborn T E,Briggs M R. Identification of a novel sterol-independent regulatory element in the human low density lipoprotein receptor promoter[J].{H}Journal of Biological Chemistry,2002,(7):5214-5221.
  • 7Matsuda M,Korn B S,Hammer R E. SREBP cleavage-activating protein(SCAP)is required for increased lipid synthesis in liver induced by cholesterol deprivation and in-sulin elevation[J].{H}Genes and development,2001,(10):1206-1216.
  • 8Brown M S,Goldstein J L. The SREBP pathway:regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor[J].{H}CELL,1997,(3):331-340.
  • 9Tang J J,Li J G,Qi W. Inhibition of SREBP by a small mol-ecule,betulin,improves hyperlipidemia and insulin resist-ance and reduces atherosclerotic plaques[J].Cell Metabo-lism,2011,(1):44-56.
  • 10Yang L H,Chen T M,Yu S T. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells[J].Pharma-cological Research,2007,(3):202-208.

二级参考文献31

  • 1Grabstein K H, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 re- ceptor [ J ]. Science, 1994,264 ( 5161 ) : 965-968.
  • 2Fehniger T A,Caligiuri M A. Interleukin 15 :biology and relevance to human disease [ J ]. Blood, 2001,97 ( 1 ) : 14-32.
  • 3Ohteki T, Tada H, Ishida K, et al. Essential roles of DC-derived IL- 15 as a mediator of inflammatory responses in vivo[ J]. JEM ,2006, 203 ( 10 ) : 2329-2338.
  • 4Boyiadzis M, Memon S, Carson J,et al. Upregulation of NK cell ac-tivating receptors following allogeneie hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels [ J ]. Biol Blood Marrow Transplant ,2008,14(3 ) :290-300.
  • 5Gill N, Ashkar A A. Overexpression of interleukin-15 compromises CD4-dependent adaptive immune responses against herpes simplex virus 2[J]. Virology,2009,83 (2) :918-926.
  • 6Ogasawara K,Hida S,Azimi N,et al. Requirement for IRF-I in the microenvironment supporting development of natural killer cells [ J]. Nature,1998,391(1) :700-703.
  • 7Washizu J, Nishimura H, Nakamura N, et al. The NF- kappaB binding site is essential for transcriptional of the IL-15 gene [ J ]. Immunogenetics, 1998,48 ( 1 ) : 1-7.
  • 8Azimi N, Brown K, Bamford R N, et al. Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene tran- scription through an NF-kappaB site [ J ]. Proc Natl Acad Sci USA, 1998,95 (5) :2452-2457.
  • 9Kozak M. Regulation of translation in eukaryotie systems[ J]. Annu Rev Cell Dev Biol,1992,8:197-225.
  • 10FiorentinoD F, Bond M W, Mosmann TR, et al. Th2 clones secret a factor that inhibits cytokine roduction by Thl clone [ J]. J Exp Med, 1989,170 - 208.

共引文献3

同被引文献20

  • 1BERLANGA A, GUIU-JURADO E, PORRAS J A, et al. Molecular pathways in non-alcoholic fatty liver disease[J]. Clinical and Experimental Gastroenterology, 2014, 7: 221-239.
  • 2THAN N N,NEWSOME P N. A concise review o{ non-al- coholic fatty liver disease [J]. Atheroselerosis, 2015, 239(1) .. 192-202.
  • 3FAN J G, FARRELL G C. Epidemiology of non-alcoholic fatty liver disease in China[J].Journal of Hepatology, 2009,50(1) :204-210.
  • 4MUSS(?) G, GAMBINO R, CASSADER M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver dis- ease (NAFLD)[J]., Progress in Lipid Research, 2009, 48(1):1-26.
  • 5GADDINI M, MORELLI M, BUZZIGOLI E, et al. Non-al- coholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease[J]. Nutrients, 2013, 5 (5): 1544-1560.
  • 6PETTAS, MURATORE C, CRAXIA. Non-aleoholie fatty liver disease pathogenesis: the present and the future[J]. Digestive and Liver Disease,2009,41(9):615-625.
  • 7HARDWICK J P, OSEI-HYIAMAN D,WILAND H, et al. PPAR/RXR regulation of fatty acid metabolism and fatty acid omega-hydroxylase (CYP4) isozymes., implications for prevention of lipotoxicity in fatty liver disease[J]. PPAR Resourse, 2009,2009 : 952734.
  • 8MELI R,MATTACE R G,CALIGNANO A. Role of innate Immune response in non-alcoholic fatty liver disease: meta- bolic complications and therapeutic tools[J].Frontiers in Immunology, 2014,5 : 177.
  • 9ZHANG Wenfeng, WU Yakun, MU Di, et al. Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease[J]. Annals of Hepatology: Official Journal of the Mexican Association, 2014,13 (5) : 489-495.
  • 10HU C, KITTS D D. Luteolin and luteolin-7-O-glucoside from dandelion flower suppress iNOS and COX-2 in RAW264. 7 cells[J]. Molecular and Cellular Biochemis- try, 2004,265 (1/2) .. 107-113.

引证文献2

二级引证文献8

合肥工业大学学报（自然科学版）
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部